Clinical Trials
34
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (33 trials with phase data)β’ Click on a phase to view related trials
Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 56
- Registration Number
- NCT03852446
- Locations
- πΊπΈ
Frontage Clinical Services, Inc., Secaucus, New Jersey, United States
Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT03372239
- Locations
- π¨π¦
INC Research/inVentiv Health, Toronto, Ontario, Canada
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 21
- Registration Number
- NCT03301636
- Locations
- πΊπΈ
University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
πΊπΈMayo Clinic - Rochester, Rochester, Minnesota, United States
πΊπΈUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 29
- Registration Number
- NCT03165188
- Locations
- πΊπΈ
Cedars-Sinai Medical Center, Los Angeles, California, United States
πΊπΈStanford University Cancer Center, Palo Alto, California, United States
πΊπΈUF Health Cancer Center, Gainesville, Florida, United States
NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 26
- Registration Number
- NCT03164603
- Locations
- πΊπΈ
University of Florida, Gainesville, Florida, United States
πΊπΈWashington University School of Medicine, Saint Louis, Missouri, United States
πΊπΈUniversity of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next